Psychedelic mushrooms grow worldwide and contain active hallucinogenic ingredients, especially Psilocybin. Psilocybin has particular healing properties that can cause an intense mystical experience if used in high doses. In addition to hallucinations, consumers said they felt extreme euphoria and a total transformation of consciousness.
However, in small doses, specialists using top selling psilocybe cubensis spores grown for research purposes, say they affect neurogenesis, increasing the size of neurons, improving connections, and counteracting symptoms of depression. Psychedelics have been recognized since the 30s as having therapeutic potential for neuropsychiatric diseases such as depression, drug addiction, and obsessive-compulsive disorders.
More recent studies on Psilocybin, an alkaloid from the family of psychedelics that exists in magic mushrooms, have begun to reveal that it has the potential to relieve the symptoms of depression. These benefits are obtained quickly, with only 2-3 microdoses, and are maintained for several months.
It seems that the number of neural connections increases by about 10%, and the neurons themselves increase by 10% on the second day after the administration of Psilocybin. This rapid and lasting growth could soon open a new era in the use of psychedelic drugs, which could slowly release the stigma that hovers around them.
Thanks to these findings, the FDA has already granted the status of “revolutionary therapy” for Psilocybin, in the treatment, under medical supervision, of major depressive disorders and decided that intense clinical trials are needed in this direction.